Abstract: Compositions and methods for detection of the stress-inducible Hsp70B? protein are disclosed. These include antibodies directed against particular amino acid regions of Hsp70B? and various peptides corresponding, or antigenically equivalent, to the regions. The ability to generate anti-Hsp70B? antibodies to defined epitopes permits a variety of in vitro and in vivo uses.

Abstract: Compositions and methods for detection of the stress-inducible Hsp70B? protein are disclosed. These include antibodies directed against particular amino acid regions of Hsp70B? and various peptides corresponding, or antigenically equivalent, to the regions. The ability to generate anti-Hsp70B? antibodies to defined epitopes permits a variety of in vitro and in vivo uses.

Abstract: Compositions and methods for detection of the stress-inducible Hsp70B? protein are disclosed. These include antibodies directed against particular amino acid regions of Hsp70B? and various peptides corresponding, or antigenically equivalent, to the regions. The ability to generate anti-Hsp70B? antibodies to defined epitopes permits a variety of in vitro and in vivo uses.

Abstract: A modulated immune response to an antigen is achieved by coadministering the antigen and a genetically-detoxified pertussis holotoxin, particularly one retaining its immunogenicity, to a host. The modulated immune response enables immunogenic compositions, including multivalent pediatric vaccines such as DTP, to be provided which produce a modulated immune response in the absence of extrinsic adjuvants such as alum. The adjuvanting effect achieved by the genetically-detoxified pertussis holotoxin enables at least the same level of adjuvanting effect to be achieved as previously attained by alum, without the undesirable side effects thereof.

Abstract: Compositions and methods for detection of the stress-inducible Hsp70B? protein are disclosed. These include antibodies directed against particular amino acid regions of Hsp70B? and various peptides corresponding, or antigenically equivalent, to the regions. The ability to generate anti-Hsp70B? antibodies to defined epitopes permits a variety of in vitro and in vivo uses.

Abstract: Compositions and methods for detection of the stress-inducible Hsp70B? protein are disclosed. These include antibodies directed against particular amino acid regions of Hsp70B? and various peptides corresponding, or antigenically equivalent, to the regions. The ability to generate anti-Hsp70B? antibodies to defined epitopes permits a variety of in vitro and in vivo uses.

Abstract: Compositions and methods for detection of the stress-inducible Hsp70B′ protein are disclosed. These include antibodies directed against particular amino acid regions of Hsp70B′ and various peptides corresponding, or antigenically equivalent, to the regions. The ability to generate anti-Hsp70B′ antibodies to defined epitopes permits a variety of in vitro and in vivo uses.

Abstract: A modulated immune response to an antigen is achieved by coadministering the antigen and a genetically-detoxified pertussis holotoxin, particularly one retaining its immunogenicity, to a host. The modulated immune response enables immunogenic compositions, including multivalent pediatric vaccines, such as DTP, to be provided which produce a modulated immune response in the absence of extrinsic adjuvants, such as alum. The adjuvanting effect achieved by the genetically-detoxified pertussis holotoxin enables at least the same level of adjuvanting effect to be achieved as previously attained by alum, without the undesirable side effects thereof.

Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.

Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.

Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.

Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogs are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.

Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these toxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.

Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these toxin analogues are detoxified, retain an immunodominant S1 epitope, are immunoganic and are protective in the standard pertussis vaccine potency test in mice.